Electrophysiologic and clinical effects of XXXX for recurrent paroxysmal supraventricular tachycardia.

@entity6237 @entity1 @entity591 @entity713
The antiarrhythmic effects of @entity6237 were evaluated in 9 @entity1 with paroxysmal @entity713 ( @entity713 ) @entity591 and 17 @entity1 with @entity591 . An electrophysiologic study was performed before and after intravenous @entity6237 , 2 mg/kg body weight, was infused over 15 minutes and was followed by a maintenance infusion of 1.6 mg/kg given over 1 hour to 26 @entity1 and during oral treatment to 15. Treatment with oral @entity6237 was continued for 14 +/- 5 months. Intravenous @entity6237 terminated @entity713 @entity591 by blocking the retrograde fast pathway conduction in 7 of 7 @entity1 and @entity591 by blocking retrograde conduction in the extranodal pathway in 10 of 10 @entity1 . @entity713 @entity591 and @entity591 were noninducible in 8 of 9 @entity1 (90%, p less than 0.001) and 11 of 17 @entity1 (65%, p less than 0.001), respectively. Long-term treatment with oral @entity6237 suppressed @entity713 @entity591 and @entity591 in 8 of 9 @entity1 (90%, p less than 0.001) and 11 of 17 @entity1 (65%, p less than 0.001), respectively. A favorable outcome was associated with block in the accessory pathway after intravenous @entity6237 and noninducibility during oral treatment. Recurrences preferentially occurred in the younger @entity1 . @entity6237 is effective in the acute and long-term management of paroxysmal supraventricular reentry @entity591 by suppressing conduction through the retrograde fast limb of the @entity591 circuit. The clinical effect can be predicted by electrophysiologic testing.
